Is cardiac resynchronization therapy cost-effective?

Details

Serval ID
serval:BIB_D128068EB245
Type
Article: article from journal or magazin.
Collection
Publications
Title
Is cardiac resynchronization therapy cost-effective?
Journal
Europace
Author(s)
Boriani G., Biffi M., Martignani C., Valzania C., Diemberger I., Bertini M., Domenichini G., Ziacchi M., Branzi A.
ISSN
1532-2092 (Electronic)
ISSN-L
1099-5129
Publication state
Published
Issued date
11/2009
Peer-reviewed
Oui
Volume
11 Suppl 5
Pages
v93-7
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Cardiac resynchronization therapy (CRT) is a treatment of proven efficacy for selected patients with heart failure and associated conduction disturbances. The increasing financial burden that healthcare systems face has increased the interest in cost-effectiveness and cost-utility estimates, focused on devices with defibrillation capabilities (CRT-D), with a high upfront cost, as well as on simpler devices providing only biventricular pacing (CRT-P). Available economic estimates are largely dependent on data source, assumptions, modelling technique, time horizon, and perspective, leading to some variability in cost-effectiveness and cost-utility estimates. As a whole, cost-effectiveness and cost-utility estimates of both CRT-P and CRT-D improve as the time horizon examined is lengthened and appear to be below US$50,000 per quality-adjusted life-year, a threshold value commonly adopted for coverage of healthcare interventions in the USA and quite comparable with similar thresholds used within Europe. Limited data are available on the comparative cost-effectiveness or cost-utility of CRT-P and CRT-D devices. Moreover, more data on the effectiveness and long-term benefits of CRT-D and CRT-P are needed in order to estimate better the value of these treatments in the 'real world, as well as for attempts to improve cost-effectiveness through improved patient selection.
Keywords
Cost-Benefit Analysis, Defibrillators/economics, Delivery of Health Care/economics, Europe, Heart Failure/economics, Heart Failure/therapy, Humans, Pacemaker, Artificial/economics, Patient Selection, Quality-Adjusted Life Years, Treatment Outcome, United States
Pubmed
Web of science
Open Access
Yes
Create date
03/03/2024 18:09
Last modification date
11/03/2024 7:17
Usage data